Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Ganglionic GFAP+ glial Gq-GPCR signaling enhances heart functions in vivo
Alison Xiaoqiao Xie, Jakovin J. Lee, Ken D. McCarthy
Alison Xiaoqiao Xie, Jakovin J. Lee, Ken D. McCarthy
View: Text | PDF
Research Article Cardiology Neuroscience

Ganglionic GFAP+ glial Gq-GPCR signaling enhances heart functions in vivo

  • Text
  • PDF
Abstract

The sympathetic nervous system (SNS) accelerates heart rate, increases cardiac contractility, and constricts resistance vessels. The activity of SNS efferent nerves is generated by a complex neural network containing neurons and glia. Gq G protein–coupled receptor (Gq-GPCR) signaling in glial fibrillary acidic protein–expressing (GFAP+) glia in the central nervous system supports neuronal function and regulates neuronal activity. It is unclear how Gq-GPCR signaling in GFAP+ glia affects the activity of sympathetic neurons or contributes to SNS-regulated cardiovascular functions. In this study, we investigated whether Gq-GPCR activation in GFAP+ glia modulates the regulatory effect of the SNS on the heart; transgenic mice expressing Gq-coupled DREADD (designer receptors exclusively activated by designer drugs) (hM3Dq) selectively in GFAP+ glia were used to address this question in vivo. We found that acute Gq-GPCR activation in peripheral GFAP+ glia significantly accelerated heart rate and increased left ventricle contraction. Pharmacological experiments suggest that the glial-induced cardiac changes were due to Gq-GPCR activation in satellite glial cells within the sympathetic ganglion; this activation led to increased norepinephrine (NE) release and beta-1 adrenergic receptor activation within the heart. Chronic glial Gq-GPCR activation led to hypotension in female Gfap-hM3Dq mice. This study provides direct evidence that Gq-GPCR activation in peripheral GFAP+ glia regulates cardiovascular functions in vivo.

Authors

Alison Xiaoqiao Xie, Jakovin J. Lee, Ken D. McCarthy

×

Figure 5

CNO administration increases heart rate in P0-Cre+/–::hM3Dq+/– mice.

Options: View larger image (or click on image) Download as PowerPoint
CNO administration increases heart rate in P0-Cre+/–::hM3Dq+/– mice.
(A)...
(A) Cre recombinase activity can be detected in a very small subset of neuronal-like cells in the adult brain of P0-Cre+/–::TRAP+/– mice (original magnification, 20×; scale bars: 100 μm). (B) Cre recombinase activity detected in AHiPM and hippocampus is restricted to neurons in the brain, and not detected in astrocytes, oligodendrocytes, or microglia. AHiPM, posteromedial hippocampal amygdala. (C) A small subset of SGCs in the sympathetic ganglia also exhibit Cre recombinase activity in P0-Cre mice. Scale bars: 40 μm. (D) CNO administration (0.5 mg/kg, i.p.) led to increases in heart rate in P0-Cre+/–::hM3Dq+/– mice but not in littermate control floxed-hM3Dq mice (2-way ANOVA, ***P < 0.0001, P0-Cre–/–::hM3Dq–/fl, n = 11; P0-Cre+/–::hM3Dq+/–, n = 15). (E) CNO administration (0.5 mg/kg, i.p.) did not result in changes in left ventricular contractility in P0-Cre+/–::hM3Dq+/– mice (unpaired t test, P0-Cre–/–::hM3Dq–/fl, n = 5; P0-Cre+/-::hM3Dq+/–, n = 11).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts